ClinicalTrials.gg
Not yet recruitingNCT07907718Updated Oct 30, 2026

Cognitive-Motor Training for Gait Adaptability in Parkinson Disease

An interventional study of Cognitive-motor training and Conventional physiotherapy in Parkinson Disease, sponsored by National Yang Ming Chiao Tung University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by National Yang Ming Chiao Tung University · Not applicable, Interventional, and Treatment

Updated Oct 30, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Cognitive-motor training combines thinking tasks with physical movements, encouraging participants to choose appropriate actions and adjust their movements according to different task demands. Training that involves stopping or changing a movement may help people with Parkinson's disease respond to changing situations. These abilities may also support walking in challenging environments, such as stepping over obstacles. However, the effects of this type of training on cognitive function, walking performance, and brain activity remain unclear. Therefore, this study aims to compare the effects of cognitive-motor co-dependent training with conventional exercise training on these outcomes in people with Parkinson's disease.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Cognitive-motor training
  • Gait adaptability
  • Executive function
  • Electroencephalography
03

In context

Parkinson Disease

4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 50 is above the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

National Yang Ming Chiao Tung University is the lead sponsor of 208 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of idiopathic Parkinson's disease
  • Stable use of prescribed antiparkinsonian medication for at least two weeks
  • Modified Hoehn and Yahr stage I to III
  • Age between 18 and 80 years
  • Ability to ambulate independently for at least 30 meters without assistive devices
  • A (MMSE) score of ≥ 24
  • Corrected vision and hearing sufficient to effectively receive external stimuli

Exclusion criteria

Exclusion Criteria:

  • The presence of any neurological, musculoskeletal, or cardiovascular disorders that could affect participation in this study
  • The presence of psychiatric disorders that could interfere with the ability to follow instructions or comply with study procedures
  • A history of brain surgery, such as deep brain stimulation (DBS)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cognitive-motor training group

    Participants receive 16 sessions of cognitive-motor training.

    Other: Cognitive-motor training

  • Active comparator
    Conventional exercise training group

    Participants receive 16 sessions of conventional physiotherapy.

    Other: Conventional physiotherapy

Interventions

  • OtherCognitive-motor training

    Cognitive-motor training is that cognitive tasks incorporated into motor tasks.

  • OtherConventional physiotherapy

    Conventional physiotherapy includes ROM exercise, stretching, strengthening exercise, and eye-hand coordination.

06

What researchers measure

Primary outcomes

  1. Gait speed

    Gait speed during obstacle crossing was measured using the GAITRite system. Continuous obstacle-crossing walking performance was assessed using the GaitUp system.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  2. Step length

    Using GAITRite system to measure step length

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  3. Step width

    Using GAITRite system to measure step width

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  4. Single support time

    Using GAITRite system to measure single support time

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  5. Gait Variability

    Gait variability during continuous obstacle crossing will be assessed using the GaitUp system and expressed as the coefficient of variation (CV = standard deviation / mean × 100%) of step time and stride length.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  6. Stride length

    Using the GaitUp system to measure stride length during continuous obstacle-crossing walking.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  7. Swing phase

    Using the GaitUp system to measure swing phase during continuous obstacle-crossing walking.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  8. Four Square Step Test

    The Four Square Step Test is a test used to assess the ability to step over objects and measures the time in seconds to navigate all four squares.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  9. Event-related potential - N2

    Measure event-related potential through electroencephalography during the Go/No-go test

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  10. Event-related potential - P300

    Measure event-related potential through electroencephalography during the Go/No-go test

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  11. Stroop color and word test

    Record numbers of corrected color words which the subject responds within 45 sec.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  12. Trail making test

    Trail making test contain part A and part B. Faster completing the test indicates better executive function.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

Secondary outcomes

  1. Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Motor symptoms will be assessed using Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Scores range from 0 to 132, with higher scores indicating greater motor impairment.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  2. Single-Leg Standing Balance

    Balance will be assessed by measuring the time, in seconds, that participants can stand on one leg. Longer standing times indicate better balance.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

  3. Montreal Cognitive Assessment

    Montreal Cognitive Assessment ranges from 0 to 30. Higher scores reflect better cognitive performances.

    Time frame: Before and after 8 weeks of intervention, as well as 4 weeks after intervention

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07907718
Responsible party
Yea-Ru Yang (Professor, National Yang Ming Chiao Tung University) — Principal investigator
First posted
Oct 30, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Yea-Ru Yang, PhD
Contact
yryang@nycu.edu.tw
+886228267279

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion